Irreversible sensorineural hearing loss due to clarithromycin

Postgraduate Medical Journal

Volumn 81, Issue 951, 2005, Pages 58-59

  Coulston, James ^a   Balaratnam, N ^a  

^a ROYAL GWENT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; MACROLIDE;

AGED; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; HAIR CELL; HUMAN; LOW DRUG DOSE; PERCEPTION DEAFNESS; REVIEW; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; FEMALE; FOLLOW-UP STUDIES; HEARING LOSS, SENSORINEURAL; HUMANS;

EID: 13244259531     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.020412     Document Type: Review

References (8)

1. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. London: BMA and Royal Pharmaceutical Society of Great Britain, January 2003.
2. Guay DR, Patterson DR, Seipman N, et al. Overview of tolerability profile of clarithromycin in preclinical and clinical trials. Drug Safety 1993;8:350-64.
3. McConnell SA, Amsden GW. Review and comparison of advanced generation macrolides clarithromycin and dirithromycin. Pharmacotherapy 1999;19:404-15.
4. Uzun C, Koten M, Kemal M, et al. Reversible ototoxic effect of azithromycin and clarithromycin on transiently evoked otoacoustic emissions in guinea pigs. J Laryngol Otol 2001;115:622-8.
5. Mintz U, Amir J, Pinkhas J, et al. Transient perceptive deafness due to erythromycin lactobionate. JAMA 1973;255:1122-3.
6. Brummett R. Ototoxic liability of erythromycin and analogues. Otolaryngol Clin North Am 1993;5:811-9.
7. Ress B, Gross E. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. Ann Otol Rhinol Laryngol 2000;109:435-7.
8. Kolkman W, Groeneveld JH, Baur HJ. Ototoxicity induced by clarithromycin. Ned Tijdschr Geneeskd 2002;146:1743-5.